Ratio Therapeutics

Ratio Therapeutics

Pharmaceuticals, 77 Sleeper St, Boston, , 2127, Massachusetts, United States, 11-50 Employees

ratiotx.com

  • twitter
  • LinkedIn

Who is RATIO THERAPEUTICS

A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the ...

Read More

map
  • 77 Sleeper St, Boston, Massachusetts, 2127, United States Headquarters: 77 Sleeper St, Boston, Massachusetts, 2127, United States
  • 2021 Date Founded: 2021
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $250 Million to $500 Million
  • tech-icon Active Tech Stack: See technologies
  • Jack Hoppin CEO:   Jack Hoppin

industries-icon Industry: Pharmaceuticals

SIC SIC Code: 2834 | NAICS Code: 325412 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from RATIO THERAPEUTICS

Ratio Therapeutics Org Chart and Mapping

Employees

Shawn Hillier

Chief Operating Officer

Andrew Novicki

Associate Director, Data Sciences

Ryan Schneider

Senior Research Associate

Morgan Lyon

Director Program Management

Katherine Ramey

Operations and Internal Projects Lead

Gabriela Anglon

Senior Operations Manager

Maha Chowdhury

Senior Research Associate, Radiochemistry

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Ratio Therapeutics

Answer: Ratio Therapeutics's headquarters are located at 77 Sleeper St, Boston, , 2127, Massachusetts, United States

Answer: Ratio Therapeutics's official website is https://ratiotx.com

Answer: Ratio Therapeutics's revenue is $250 Million to $500 Million

Answer: Ratio Therapeutics's SIC: 2834

Answer: Ratio Therapeutics's NAICS: 325412

Answer: Ratio Therapeutics has 11-50 employees

Answer: Ratio Therapeutics is in Pharmaceuticals

Answer: Ratio Therapeutics contact info: Phone number: Website: https://ratiotx.com

Answer: A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancer. Ratio Therapeutics TrilliumTM targeting scaffold combines pharmacokinetic modulation with best-in-class chelation technology to create proprietary small molecule targeting agents to attack a broad array of cancer targets. Our compounds accommodate imaging and therapeutic radioisotopes, ie "theranostics". The tunable nature of our platform combined with small-scale imaging trials in patients results in accelerated, de-risked compound selection.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access